NCT06757634
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06757634
Title Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Acronym VIKTORIA-2
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Celcuity Inc
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | TUR | ROU | POL | ITA | HUN | GRC | FRA | ESP | DEU | CZE | BRA | BGR | BEL | AUS | ARG


No variant requirements are available.